Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HIV Infection and Lymphoma Survival

Cancer Epidemiol Biomarkers Prev; ePub 2016 Oct 18; Han, et al

Publish date:: November 2, 2016

Better management strategies are needed for patients with HIV/AIDS-associated lymphoma, concluded researchers after conducting a study involving nearly 180,000 individuals.

Participants were diagnosed with Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), peripheral T-cell lymphoma (PTCL) or follicular lymphoma (FL) during an 8-year period ending in 2011. Investigators analyzed survival trends of those infected and not infected with HIV. Among the results:

The prevalence of HIV-infection was 1% for FL, 3% for PTCL, 5% for HL, 5% for DLBCL, and 29% for BL.
Patients with HIV infection were at higher risk for poor overall survival, including DLBCL (nearly twice as likely), HL (50% higher odds), BL (46% higher), PTCL (43% higher), and FL (44% higher).

Citation:

Han X, Jemal A, Hulland E, et al. HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy. [Published online ahead of print October 18, 2016]. Cancer Epidemiol Biomarkers Prev. doi:10.1158/1055-9965.EPI-16-0595.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,